Non-small-cell Lung Cancer Clinical Trial
Official title:
A Phase 2 Study of XL647 in Subjects With Non-Small-Cell Lung Cancer
NCT number | NCT00364780 |
Other study ID # | XL647-201 |
Secondary ID | |
Status | Completed |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | July 2006 |
Est. completion date | August 2010 |
Verified date | May 2022 |
Source | Kadmon Corporation, LLC |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this phase II study is to determine the safety, tolerability, and activity of XL647 in previously untreated subjects with non-small cell lung cancer (NSCLC). XL647 is a small molecule that potently inhibits multiple receptor kinases, including EGFR, VEGFR2 (KDR), ErbB2, and EphB4. Sensitivity to EGFR inhibitors has been linked to specific EGFR mutations and associated with certain clinical characteristics in patients with NSCLC (eg, female, minimal and remote smoking history, and adenocarcinoma histology).
Status | Completed |
Enrollment | 55 |
Est. completion date | August 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject has NSCLC with a histologically confirmed diagnosis of adenocarcinoma with measurable disease (stage IIIB, with malignant pleural effusion, and stage IV) and either has a demonstrated activating mutation of the EGF receptor in tumor tissue or meets one of three criteria: asian, female, and minimal or no smoking history. - Measurable disease defined according to RECIST - ECOG performance status of 0 or 1 - Normal organ and marrow function - No other malignancies within 5 years, except for non-melanoma skin cancer Exclusion Criteria: - Radiation to =25% of bone marrow within 30 days of XL647 treatment - Prior systemic anticancer therapy, including cytotoxic chemotherapy, anti-VEGF, anti-VEGFR, or anti-EGFR agents or investigational drug - Subject has not recovered to = grade 1 or to within 10% of baseline values from adverse events due to other medications administered > 30 days before study enrollment - Receiving anticoagulation therapy with warfarin (low-dose warfarin < 1 mg/day, heparin and low molecular weight heparins are permitted) - The subject meets any of the following cardiac criteria: - Corrected QT interval (QTc) of > 460 msec - Family history of congenital long QT syndrome or unexplained sudden death - History of sustained ventricular arrhythmias - Has a finding of left bundle branch block - Has an obligate pacemaker - Has important bradycardia defined as a heart rate of < 50 bpm due to sinus node dysfunction - Has uncontrolled hypertension - Has symptomatic congestive heart failure, unstable angina, or a myocardial infarction within the past 3 months - Has a serum potassium or serum magnesium level that falls outside the normal range - The subject has progressive symptomatic or hemorrhagic brain or leptomeningeal metastases - Uncontrolled intercurrent illness - Subject is pregnant or breastfeeding - Known HIV |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | University of Chicago | Chicago | Illinois |
United States | Case Western Reserve University, University Hospitals of Cleveland | Cleveland | Ohio |
United States | Wayne University, Wertz Clinical Cancer Center, Karmanos Center | Detroit | Michigan |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Hematology Oncology Associates of the Treasure Coast | Port Saint Lucie | Florida |
United States | Carle Cancer Center | Urbana | Illinois |
Lead Sponsor | Collaborator |
---|---|
Kadmon Corporation, LLC |
United States,
Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. J Thorac Oncol. 2012 May;7(5):856-65. doi: 10.1097/JTO.0b013e31824c943f. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate | Inclusion until disease progression | ||
Primary | Safety and tolerability | Inclusion until 30 days post last treatment | ||
Secondary | Progression-free survival | Inclusion until disease progression or death | ||
Secondary | Duration of response | Inclusion until disease progression | ||
Secondary | Overall survival | Inclusion until 180-Day Follow-up post last treatment | ||
Secondary | Pharmacokinetic and pharmacodynamic parameters | At various time points from pre-dosing until post dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Completed |
NCT02965391 -
Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients
|